Results 51 to 60 of about 11,492 (188)

Decreased Severity of Oral Immunotherapy Induced Gastrointestinal Eosinophilic Reactions Following Revisions in Milk‐Treatment Protocol

Allergy, EarlyView.
A revised milk OIT protocol with lower daily allergen load and slower dose escalation reduced the severity and delayed onset of OIT‐induced gastrointestinal eosinophilic reactions (OITIGER). Elevated baseline absolute eosinophil count (AEC > 600/μL) was a consistent independent risk factor for OITIGER, while older age was protective.
Na'ama Epstein‐Rigbi, Matan Elkan, Yair Tzarfati, Michael B. Levy, Liat Nachshon, Yael Koren, Yitzhak Katz, Arnon Elizur, Michael R. Goldberg   +8 more
wiley   +1 more source

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada

Patient Preference and Adherence, 2020
Jason K Lee,1 Suvina Amin,2 Michelle Erdmann,3 Atif Kukaswadia,4 Jelena Ivanovic,5 Aren Fischer,4 Alain Gendron6 1Clinical Immunology and Allergy, Internal Medicine, Evidence Based Medical Educator Inc.
Lee JK, Amin S, Erdmann M, Kukaswadia A, Ivanovic J, Fischer A, Gendron A   +6 more
doaj  

Basophil Activation Test as Biomarker of Severity and Threshold of Allergic Reactions to Cow's Milk During Oral Food Challenges

Allergy, EarlyView.
The threshold of reactivity during fresh milk challenges was 70% lower than that of baked milk challenges, reflecting the higher allergenicity of fresh milk. BAT was the only biomarker statistically significantly different between severity and threshold groups, for baked milk and fresh milk allergies, respectively.
Holly Boyd, Irene Bartha, Ru‐Xin Foong, Marta Krawiec, Andreina Marques‐Mejias, Hannah F. Marshall, Suzana Radulovic, Faye Harrison, Grammatiki Antoneria, Zainab Jama, Matthew Kwok, Ewa Pietraszewicz, Malak Eghleilib, Cristian Ricci, Tom Marrs, Gideon Lack, George Du Toit, Alexandra F. Santos   +17 more
wiley   +1 more source

Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI

Journal of Allergy and Clinical Immunology: Global
Background: Omalizumab provides clinical benefits to a fraction of patients with asthma. It remains unclear why some patients do not respond to omalizumab therapy.
Agnes Yang, BS, Chao Gu, PhD, Katherine Upchurch, PhD, Adrien Caffiers, MS, Mark Millard, MD, Laurie Baert, PhD, HyeMee Joo, PhD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

Allergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar   +22 more
wiley   +1 more source

Neutralizing serum IgE upregulates CD88 and CRTH2 expression on basophils in patients with asthma

Journal of Allergy and Clinical Immunology: Global
Background: The cross-linking of FcεRI by IgE and allergen leads to the degranulation of basophils and mast cells, which can drive allergic reactions. Neutralizing IgE with omalizumab could thus offer clinical benefits to a subset of patients with asthma.
Agnes Yang, BS, Laurie Baert, PhD, Katherine Upchurch, PhD, Matthew Wiest, PhD, Jacob Turner, PhD, HyeMee Joo, PhD, Mark Millard, MD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Omalizumab: Clinical Use for the Management of Asthma

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2012
Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with moderate to severe allergic asthma whose asthma is poorly controlled with inhaled corticosteroids and inhaled long-acting β 2 agonist
Neil C. Thomson, Rekha Chaudhuri
doaj   +1 more source

Serum free IgE guided dose reduction of omalizumab: a case report

Allergy, Asthma & Clinical Immunology, 2017
Background Omalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for ...
Yasuhiro Gon, Reiko Ito, Shuichiro Maruoka, Kenji Mizumura, Yutaka Kozu, Hisato Hiranuma, Yuko Iida, Sotaro Shikano, Shu Hashimoto   +8 more
doaj   +1 more source

Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab [PDF]

, 2011
Chronic idiopathic urticaria is a condition that is often controllable with antihistamine therapy. However, some patients have disease burden that is difficult to manage, non-responsive to antihistamines and often requires immunosuppressive medications ...
Michael C Saavedra, Sanjiv Sur
core   +2 more sources

A Systematic Review and Meta‐Analysis on the Induction of Confirmed Eosinophilic Esophagitis as a Side Effect of Allergen Immunotherapy: An EAACI Task Force Report

Allergy, EarlyView.
ABSTRACT The European Academy of Allergy and Clinical Immunology (EAACI) established a Task Force to assess the existing data on the relationship between eosinophilic esophagitis (EoE) and allergen immunotherapy (AIT). This systematic review and meta‐analysis aimed to study the incidence of confirmed EoE, developing as a side effect of AIT to food or ...
Carlo Maria Rossi, Ingrid Terreehorst, Evaggelia Apostolidou, Martina Votto, Arzu Bakirtas, Antonella Cianferroni, George N. Konstantinou, Katerina Pantavou, Dario Antolin‐Amerigo, Enrico Heffler, Alberto Alvarez‐Perea, Montserrat Fernandez‐Rivas, Georgios K. Nikolopoulos, Oliver Pfaar, Constantinos Pitsios   +14 more
wiley   +1 more source